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Brief Overview of Selected Aspects of
Testicular Hormone Action
by Leslie P. Bullock*
This paper is designed to give an overview of the mechanism of androgen action and some of
the factors that can affect it. The discussion ofandrogen action includes androgen transport in
the blood, metabolism, receptor binding, nuclear activation and selected aspects of biological
response. The importance of recognizing interspecies and interstrain differences in specific
aspects ofandrogen action is mentioned. Some examples ofthe effects ofenvironmental agents
on androgen metabolism, receptor binding and biological response are included.
Introduction
It has been recognized for some time that toxins
can have far-reaching effects within the human
body. Although it is only now coming under study,
hormone action may be particularly susceptible to
environmental factors due to the many steps in-
volved in its manifestation. The testis is known to
secrete several different hormones. The actions of
two ofthem, inhibin and mullerian inhibiting factor,
are not well defined and I will not discuss them
further. The action of estrogen, which may be a
major testicular product in some species, will be
discussed in a later session.
The major focus of this paper will be on the
mechanism of androgen action. Space does not
permit me to go into the intricate details involved.
These can be obtained from numerous reviews.
Instead, I want to give an overview and to eluci-
date some general points that should be considered
by toxicologists studying the mechanism of, or the
effects of any compound on, androgen action.
It is necessary to consider a number of different
aspects when evaluating a compound for its effect
on androgen action. The biological efficacy of an
androgen is influenced by its rate of synthesis or
entry into the circulation, its metabolism in target
and peripheral tissues, its availability for uptake by
the target organs as well as its biochemical action
within the target cell itself.
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In my study of androgen action, I have used
primarily the mouse kidney (1-5). This organ offers
several advantages. Although it is not androgen-
dependent for its differentiation, it is androgen-
responsive. Androgen receptors are present in both
males and females. The kidney responds to andro-
gens with cellular hypertrophy, but not hyperpla-
sia, of Bowman's capsule and the proximal convo-
luted tubule. The absence of cell division means a
constant population of cells is available for study.
The activity of a number of specific enzymes
including ,-glucuronidase, 3-galactosidase, d-amino
acid oxidase, alcohol dehydrogenase, and arginase
are increased by androgens. There are a number of
genetic mutants, with altered androgen responsive-
ness, which provide powerful tools for disecting the
regulation of androgen action (6-8). We have made
extensive use of the androgen-insensitive Tfm/Y
mouse (3). The androgen insensitivity is a result of
the effective absence of androgen receptors. Al-
though male accessory sex tissues do not develop,
severalnon-androgen-dependenttissuesremainwhich
are androgen-responsive in the normal animal. The
Tfm/Y mouse has been extremely useful for deter-
mining those effects that are mediated via the
androgen receptor.
Circulation
Some ofthe factors affecting testicular androgen
biosynthesis were discussed by Ewing (9). Once
secreted into the blood, free androgens circulate in
11equilibrium with androgens bound to plasma bind-
ing proteins. The plasma protein with the highest
binding affinity for androgens is sex hormone
binding globulin (TeBG or SHBG). This protein is
present in some species such as man, nonhuman
primates, rabbits, and sheep but not in others
including rodents, dogs, cats, and birds (10). In
these latter species, testosterone is bound primar-
ily to albumin. Some potent synthetic androgens,
such as R1881, are not bound by TeBG which may,
in part, account for their increased androgenicity.
Any agents, such as estrogens or drugs that alter
the synthesis and thus, the plasma concentration,
of hormone binding proteins will ultimatelv affect
the rates of testosterone biosynthesis and metabo-
lism (11, 12).
Metabolism
Androgens are metabolized in the liver, lung and
other peripheral tissues as well as in the target
organs themselves. In the liver and lung, this
metabolism is primarily degradative. Changes in
degradative enzymatic activities can alter the met-
abolic clearance rate and, thus, the effective biolog-
ical activity of a hormone. While some hepatic
steroid metabolizing enzymes function constitutively,
the activity ofothers may be affected by hormones,
drugs ortoxins (13-15). Some hepatic enzymes need
a defined hormonal milieu during a critical neonatal
period for normal activity to develop in the adult
(15). Species differences in the mode of regulation
and activity of hepatic steroid metaboliiing en-
zymes may result in differences between species in
thebiological activityofandrogens. We havereported
marked species differences in the clearance rate
and the effect on hepatic metabolism of several
synthetic progestins known to affect androgen
action (16). These differences in hepatic metabolism
are just one reason why data on biological activity
gained in one species, or for that matter one strain,
does not necessarily apply to another.
In target organs testosterone may be reduced to
5ao-dihydrotestosterone or aromatized to estrogens
[Eq. (1)]. In initial studies of nuclear androgen
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endogenous male hormone. This is in contrast to
estrogen and progesterone target tissues, in which
the active steroid is uniformly the major steroid
secreted by the gonad. However, when we injected
3H-testosterone into mice we found only unmetab-
olized 3H-testosterone in renal nuclei (Fig. 1) (5).
Subsequent work by ourselves and others have
demonstrated that in androgen target tissues, the
active steroid maybe testosterone or DHT depending
on the presence or absence of the enzyme 5a-
reductase (18). As data have accumulated it has
become evident that not only are there differences
in the active androgen between tissues ofthe same
species but that there may also be differences
between species when only a single tissue is com-
pared. Generally, in the adult animal, 5oL-reductase
is low to absent in kidney, muscle, submandibular
gland and testis and present in skin, accessory sex
tissues and portions of the brain and pituitary. In
those tissues that lack 5a-reductase, exogenous
administration of DHT will also induce nuclear
uptake and androgenic responses in these tissues
(Fig. 1), since the androgen receptor will bind
either testosterone or DHT with high affinity.
Since the biological responses to all steroids are
initiated in the nucleus, it is important to determine
the active intranuclear form of any compound that
works via a steroid receptor. The compound injected
or found in highest concentration in the blood is not
necessarily what is concentrated in the nucleus.
An interesting example of the importance of
target organ metabolism in determining the active
steroid is given by the study of Wilson and col-
leagues on the sexual differentiation of the human
and rabbit fetus (19, 20). They showed that, al-
though DHT is the active androgen in all male
accessory sex tissues in the adult, in utero, testos-
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uptake in rat prostate 'H-5u-dihydrotestosterone
(DHT) was found after an injection of3H-testosterone
(17). Thus, DHT was thought to be the active
12
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FIGURE 1. 'H-androgens isolated from female mouse kidney
nuclei following the IV administration of the TH-steroid
indicated (5).
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differentiation ofWolffian ducts. This is due to the
fact that although 5ot-reductase activity is present
in the urogenital sinus and external genitalia at the
time ofdifferentiation, the enzyme does not become
active until later in Wolffian ducts. The require-
ment for 5a-DHT for the differentiation of some
accessory sex tissues is demonstrated by men with
an inherited defect in 5a-reductase activity (21).
Affectedpatients havetestesaswellasepididymidies,
vas and seminal vesicles derived from Wolffian
ducts. However, due to the absence of DHT, they
lack well differentiated prostate and male external
genitalia.
DHT may be further metabolized to the weakly
androgenic 3a- and 3,B-androstanediols. These com-
pounds may derive their activity through back-
conversion to DHT, as in the mouse kidney, or they
may have direct effects as has been reported forthe
prostate (18). It is important to be aware of the
activity of steroid-metabolizing enzymes in target
tissues in any study of steroid action in which
steady state kinetics is required. We found that,
although testosterone was not metabolized in mouse
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FIGURE 2. Mouse kidney slices were incubated (37°C) with
either 3H-testosterone or 3H-dihydrotestosterone and the
substrate remaining quantified (4).
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kidney, DHT was converted to the androstanediols
at a rapid rate even at 4°C (Fig. 2) (1).
The importance of aromatization of testosterone
in the sexual differentiation and subsequent func-
tion ofthe brain was first suggested by Naftolin et
al. in 1972 and since then has received a great deal
ofattention (22, 23). Information on the role ofsex
steroids in the sexual development ofthe brain has
been difficult to obtain, however. Use ofhuman and
rodent genetic mutants, enzyme blockers, and
routine metabolic studies, indicate that although
there are species differences, testosterone, DHT,
and the estrogens have specific, essential roles in
the normal development of the sexual function of
the brain, and thus, secondarily, the reproductive
tract as well as other peripheral tissues of both
males and females. Aromatase activity, converting
testosterone to estradiol, is highest in those parts
ofthe brain that have been associated with regula-
tion of reproductive function, i.e., the anterior
hypothalamus, and preoptic area and a portion of
the amygdala. Critical periods exist during fetal
and neonatal life during which the proper hormone
must be present if normal sexual differentiation of
the brain is to occur. The results of this early
differentiation may not be manifested until later
when the animal goes through puberty.
The recognition that the brain can further me-
tabolize estrogens to catechol estrogens extends
the potential sphere of influence that testosterone
may have within this organ. Catechol estrogens
may act as competitive inhibitors ofthe inactivation
of catecholamines by acting as substrate for
catechol-O-methyltransferase. They, thus, have the
potential to influence the biosynthesis and inactiva-
tion of dopamine and norepinephrine. Catechol
estrogens have also been reported to affect gonado-
tropin regulation.
From the above discussion it should be apparent
that metabolism of a steroid plays an important
part in determining its activity. Any factor which
alters this metabolism, whether it be peripheral or
within the target organ itself, could evoke major
alterations in biological activity.
Receptor Binding
Androgen action is initiated via binding of the
compound to the androgen receptor and transloca-
tion of the steroid-receptor complex into the nu-
cleus (5, 18, 22, 24-26). However, despite their
similarity in one-dimensional structure, not all
steroids induce androgenic responses nor do all
tissues respond. This specificity is, in part, due to
the presence of hormone-specific receptor proteins
in target tissues. As receptor assays become more
13and more sensitive, androgen receptors have been
found in an increasing number of tissues. These
include the male accessory sex tissues, testes,
hypothalamus, preoptic region, pineal organ, pitu-
itary, muscle, skin, uterus, vagina, kidney, and
preputial, sebaceous, and submaxillary glands of a
variety ofspecies. The androgen receptor is thought
to be similar in all tissues of an individual and is
remarkably similar between species. In addition,
most ofthe general aspects ofhormone binding and
mechanism of action are quite similar between the
different classes of steroids.
When studying a new receptor in a "new" tissue
it is important to differentiate steroid receptors
from other proteinaceous macromolecules, such as
enzymes or carrier proteins, which may also bind
steroids. A steroid receptor can be defined as that
soluble, cytoplasmic protein which, when combined
with a specific steroid, enters the nucleus and, upon
binding of the complex to specific acceptor sites on
chromatin, stimulates nuclear responses and a new
pattern of gene expression.
Numerous in vitro studies of receptors for all
classes of steroids have demonstrated that there
are some basic biochemical features that are com-
mon to all of them. Although it is not known if the
receptor has these characteristics in the intact cell,
they should be demonstrated in vitro before any
new binder is called a receptor. These characteris-
tics include sedimentation in the 8 S region of
low-salt sucrose gradients, formation of a 4-5 S
complex upon the addition ofsalt, an acidic PI, heat
lability, high-affinity (nM) low-capacity binding,
and the intranuclear transfer of the steroid-binder
complex into the nucleus where it is retained with
high affinity.
The androgen receptor binds both testosterone
and 5a-DHT with high affinity; the Kd is in the
nanomolar range. A variety of other compounds,
not directly related to testosterone, have been
shown to exert androgenic orantiandrogenic activi-
ties via binding to the androgen receptor. These
include the synthetic progestins which may be
androgenic, such as medroxyprogesterone acetate,
or antiandrogenic, such as cyproterone acetate, the
antiandrogen, BOMT (6ot-bromo-17P-hydroxy-17o-
methyl-4-oxa-5o-androstan-3-one) and the nonster-
oidal compounds, flutamide and the antimineraloc-
orticoid, spironolactone. There are also several
reports suggesting that pesticides and herbicides
may bind to the androgen receptor (27-33). Those
compounds with androgenic activity act in a man-
ner similar to testosterone. It is not known, howev-
er, why, in the case of the antiandrogens, the
receptor complex is inactive. There may be several
different explanations.
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In a study of the binding of mouse kidney
androgen receptors to a variety ofprogestins which
have different effects on androgen action, we could
not correlate relative binding affinities of the ste-
roids, as measured in cytosol, with their biological
activity, androgenic, antiandrogenic, or inactive
(Table 1) (4). This was not surprising, considering
the number of other steps at which these com-
pounds could act to affect androgen action. Results
from other investigators suggest that additional
parameters may be more informative in predicting
and understanding these multiple biological effects.
Raynaud and colleagues have correlated antiandro-
genic activity with fast dissociation rates (34).
Sherman et al. proposed an allosteric model for
determining the biological activity of the steroid
receptor complex (35). The receptor may be either
in the active or inactive form, with the biological
action of the complex being determined by the
percent of receptor in the active form. In other
systems, antiestrogenic activity has been ascribed
to lack of entry of the receptor complex into the
nucleus, prolonged retention of the complex in the
nucleus, binding to a different class ofintranuclear
acceptor sites, or a failure to stimulate regenera-
tion of cytoplasmic receptors. The biochemical
difference between a steroid receptor when it is
bound to an agonist versus an antagonist has yet to
be elucidated. A major hindrance to the indepth
characterization of the binding of the androgen
receptor with various compounds as well as nuclear
acceptor site-receptor interactions is the absence of
a purified androgen receptor.
Nuclear Response
The binding of androgen by the receptor is
necessary for in vivo receptor "activation," such
that now the receptor, complexed with the steroid,
is translocated into the nucleus where it is bound at
specific acceptor sites on chromatin (18, 24-26, 36).
This activation step apparently represents achange
in size and conformation of the receptor with the
loss or gain of an additional protein moiety. The
intranuclear binding of the complex results in its
concentration and nuclear retention for several
hours.
While the steroid is necessary for the in vivo
activation and subsequent nuclear entry of the
receptor, it is the protein and its interaction with
chromatin that initiates subsequent events. The
androgen insensitivity ofthe Tfm/Y mouse is due to
the absence of androgen receptors so that target
tissue nuclei remain unstimulated even in the
presence of androgen. Although the activated
hormone-receptor complex can bind to DNA in a
Environmental Health PerspectivesTable 1. Comparison of the relative binding affinity (RBA) for mouse kidney androgen receptors and the relative biological
activity of C21 progestins.
Relative biological activity
Compound RBA Progestatiolial And(ii-ogenlic Anitiand(iiogenic
Cyproterone acetate 30 VerV p)oteiit () + + +
Medroxyprogesterone acetate 8 2()O + ++ ()
17ax-Hydroxy-6(x-methylprogesterone 12 () ()
6cx-Methylprogesterone 36 10() + + + +
17a-Acetoxyprogesterone 14 2,500 + + 0
17a-Hydroxyprogesterone 4 1 0 0
Progesterone 3 1(0(0 0
nonspecific fashion, the chromosomal, non-histone
proteins play an active role in regulating receptor
interaction at specific, appropriate sites within the
genome of target tissues.
The processes involved in the interaction of the
steroid receptor complex and the acceptor sites on
chromatin are not well understood. Target organ
chromatin does provide greater specificity ofaccep-
tor sites than does nontarget organ chromatin.
However, the overall apparent heterogeneity in
nuclear binding sites results in classes of acceptor
sites which differ in their binding affinity. The
biological importance of these different classes of
acceptor sites is not known.
One of the earliest responses to androgen treat-
ment that can be detected is an increase in the
activity of nuclear RNA polymerase I (nucleolar)
and II (nucleoplasmic) activity. We have shown
that a single dose of testosterone results in a
biphasic increase in RNA polymerase I and II
activity in mouse kidney nuclei (Fig. 3) (5). The
increase in activity can be detected as early as 15
min after hormone administration and peaks after
30-60 min and again after 12-20 hr. This response
was not seen in androgen-insensitive Tfm/Y mice.
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FIGURE 3. Effect of testosterone (1 mg) on RNA polymerase
activities in mouse kidney nuclei (5).
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Interestingly, the androgenic progestin, medroxy-
progesterone acetate (MPA) and the antiandrogenic
progestin, cyproterone acetate, also induced an
increase in polymerase activity. The increase in
polymerase activity in response to steroid treat-
ment may be due to an activation or an increase in
the number ofpolymerase molecules, to an increase
in template capacity or to an increase in the rate of
mRNA chain elongation. When testosterone and
MPA were compared they were found to differ in
their effects on chromatin template activity of
specific polymerase molecules and chain elongation.
It is probable that different hormones in different
tissues exert different effects on each of these
parameters. Another very early and probably very
important intranuclear response to androgen treat-
ment is the phosphorylation of nuclear non-histone
proteins including the polymerases.
Although it has been known for some time that
androgen treatment results in an increase in mRNA
synthesis in target organs, it has not been until
recently that several specific mRNA's have been
identified. These include mRNA for major urinary
protein (MUP) in mouse liver (37), ax2 globulin in
rat liver (38), aldolase (39) and prosta[tic binding
protein (40) in rat prostate and 3-glucuronidase (41)
and a protein of unknown function (42) in mouse
kidney.
Concomitant with the increase in specific mRNA's,
there is a general increase in rRNA. The overall
resultisincreased synthesis oncytoplasmicpolysomes
of specific proteins which are characteristic for the
individual target tissues involved. In some tissues a
later response is the increase in DNA polymerase
and cell division.
Biological Response
Even after the steroid receptor complex has
finally induced a nuclear response there are specific
factors which regulate the biological response of
individual end points. We have been interested in
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specific androgen effects in the mouse.
As mentioned earlier, a number of different
proteins in mouse kidney respond specifically to
androgen stimulation. In no instance was a re-
sponse obtained in Tfm/Y mice. 1-Glucuronidase
has been a most useful endpoint to study because of
its known genetic regulation. Alleles for the struc-
tural as well as the regulatory gene have been
identified (8). The regulatory gene, Gur, is specific
for 3-glucuronidase response to androgens in the
kidney and represents the only gene known to
regulate steroid response. Most mouse strains have
been found to be high (Gura) or low (Gurb) respond-
ers. This response is regulated at the level of
transcription since the degree of response is directly
correlated with differences in mRNAi3glueur nidase and 3-glucuronidase synthesis. We have snown
thatGuralsoregulates theresponse ofglucuronidase
to the androgenic progestin, medroxyprogesterone
acetate (Fig. 4) (4). This is further evidence that
Gur is related to androgen receptor-chromatin
interaction.
Another as yet incompletely described, regula-
tion of glucuronidase response is hypophysectomy
(8). Although the androgen response of several
other renal enzymes remains unaffected, the re-
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FIGURE 4. Effect of (-) testosterone and (--) medroxy-
progesterone acetate on mouse kidney 3-glucuronidase activ-
ity in a strain with Gura/a (A/J) and Gurb7b (C57BL/6 J) type
response. Steroid (1 and 3 mg, respectively) was administered
daily (4).
sponse of glucuronidase synthesis and activity is
greatly reduced. Even so, the difference between
Gura and Gurb responses is maintained. Adminis-
tration of growth hormone or prolactin will par-
tially restore the response.
We have also done a few studies in the area of
toxicology. CHC13 and dimethylnitrosamine (DMN)
are extremely active in male kidney but not so in
female kidney. Both the toxicity of CHC13 and the
metabolism ofDMN to a mutagen can be induced in
females by treatment with testosterone orandrogenic
progestins (43-45). These effects of androgens are
mediated via the androgen receptor as suggested
by the insensitivity of the Tfm/Y mouse and the
inhibition by antiandrogens. In both instances,
marked interstrain differences were noted. In nei-
ther case did the differences correlate with differ-
ences in glucuronidase responsiveness. The effects
on liver were not affected by androgen treatment.
Species and strain differences were also noted for
liver when the hepatic response of ethylmorphine
N-demethylase to testosterone and several syn-
thetic C21 progestins was studied (46). It is, thus,
evident that androgens can have important effects
on drug metabolism or the manifestation of toxic
effects.
From the above examples it should be obvious
that tissue and specific genetic factors may have
major effects on the expression of the final biologi-
cal response. In the study of the effects of any
androgen or other compound capable of affecting
androgen action it is important to study the re-
sponse in several tissues and, ifpossible, in several
strains or species. The latter is particularly impor-
tant when animals as unique as inbred strains of
mice are used. Animals with definitive mutations
may offer useful probes for the further understand-
ing of the biochemical action of androgens and the
factors that affect it.
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